Outlook Therapeutics
Outlook Therapeutics

Outlook Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

$152.3M

Market Cap • 9/29/2026

2010

(16 years)

Founded

2016

(10 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

152,3M

EV

159,5M

EV/Revenue

-137,1

EV/EBITDA

-2,9

EV/EBIT

-2,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-42,9%

Total Yield

-42,9%

Payout

0%

Retained Earnings

-653,5M

Profitability

Gross Margin

195,6%

EBITDA Margin

4772,9%

EBIT Margin

4781,8%

Net Margin

5253,5%

D&A/EBITDA

0%

R&D/Revenue

-1492,5%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,7%

% Goodwill

0%

ROE

256,9%

ROIC

—

Growth

CAGR Op. Income 5Y

2,9%

CAGR Net Income 5Y

4,2%

CAGR EPS 5Y

-31,8%

CAGR OCF 5Y

-0,4%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

0,8

Quick Ratio

0,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium